Advertisement

Topics

Sosei Regains Worldwide Rights from Teva to Develop and Commercialize ...

00:15 EDT 14 Mar 2018 | Topix

Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headaches Sosei Group , the world leader in GPCR medicine design and development, announced that it has regained worldwide rights from Teva Pharmaceutical Industries Ltd. to develop and commercialize lead candidate HTL0022562 and other novel small molecule CGRP antagonists for the treatment of migraine and other severe headaches. HTL0022562 is a novel, potent, and highly selective small molecule CGRP antagonist designed by Sosei's wholly-owned subsidiary Heptares Therapeutics using its proprietary structure-based drug design platform.

Original Article: Sosei Regains Worldwide Rights from Teva to Develop and Commercialize ...

NEXT ARTICLE

More From BioPortfolio on "Sosei Regains Worldwide Rights from Teva to Develop and Commercialize ..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...